Advanced Accelerator Applications (NASDAQ: AAAP) and Aimmune Therapeutics (NASDAQ:AIMT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Insider & Institutional Ownership

42.0% of Advanced Accelerator Applications shares are owned by institutional investors. Comparatively, 72.9% of Aimmune Therapeutics shares are owned by institutional investors. 24.6% of Aimmune Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Advanced Accelerator Applications and Aimmune Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Advanced Accelerator Applications 0 1 4 0 2.80
Aimmune Therapeutics 0 0 2 0 3.00

Advanced Accelerator Applications presently has a consensus price target of $56.50, suggesting a potential upside of 0.05%. Aimmune Therapeutics has a consensus price target of $36.67, suggesting a potential upside of 57.91%. Given Aimmune Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Aimmune Therapeutics is more favorable than Advanced Accelerator Applications.

Volatility & Risk

Advanced Accelerator Applications has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Aimmune Therapeutics has a beta of -1.1, meaning that its stock price is 210% less volatile than the S&P 500.

Earnings & Valuation

This table compares Advanced Accelerator Applications and Aimmune Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Advanced Accelerator Applications $148.26 million 16.82 -$20.01 million ($0.88) -64.17
Aimmune Therapeutics N/A N/A -$106.22 million ($2.25) -10.32

Advanced Accelerator Applications has higher revenue and earnings than Aimmune Therapeutics. Advanced Accelerator Applications is trading at a lower price-to-earnings ratio than Aimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.


This table compares Advanced Accelerator Applications and Aimmune Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Advanced Accelerator Applications -33.83% -16.05% -11.18%
Aimmune Therapeutics N/A -44.53% -42.00%


Advanced Accelerator Applications beats Aimmune Therapeutics on 7 of the 12 factors compared between the two stocks.

About Advanced Accelerator Applications

Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. The Company has a portfolio of nine diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. Its commercial products include Gluscan/Gluscan 500/Barnascan, FluoroChol, MIBITEC/Adamibi, DOPAVIEW, Leukokit, Neurolite, SomaKit and NETSPOT. Additional MND product candidates include Annexin V-128, a SPECT product candidate for the imaging of apoptotic and necrotic lesions with potential applications in a range of indications.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company’s lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.

Receive News & Ratings for Advanced Accelerator Applications S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Accelerator Applications S.A. and related companies with's FREE daily email newsletter.